Neuren Pharmaceuticals Banner Image

Neuren Pharmaceuticals

  • Ticker NEU
    Exchange ASX More
  • Industry Biotechnology More
  • Sector Healthcare More
Neuren Pharmaceuticals Logo Image
  • 1-10 Employees
  • Based in Camberwell, Australia
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for theMore treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes.
4.8 / 5.0 (117)

Neuren Pharmaceuticals reports have an aggregate usefulness score of 4.8 based on 117 reviews.

Neuren Pharmaceuticals

Most Recent Annual Report

Neuren Pharmaceuticals
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Neuren Pharmaceuticals Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!